Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib in Recurrent/Metastatic Esophageal Squamous Cell Carcinoma
NCT02353936Phase 2Unknown
- Sponsor
- Yonsei University
- Start
- Jan 2015
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afatinib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Yonsei University. Primary endpoint: Objective Response Rate at 2 years. Status: unknown.
02
Drugs
afatinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT02353936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02353936.